Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial

Highlights•An investigational NTHi vaccine was tested for the first time in adults with COPD. •The vaccine had acceptable safety and reactogenicity. •Vaccine-elicited antibody concentrations were higher than baseline 1 year post-dose 2.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2019-09, Vol.37 (41), p.6102-6111
Hauptverfasser:	Wilkinson, Tom M.A, Schembri, Stuart, Brightling, Christopher, Bakerly, Nawar D, Lewis, Keir, MacNee, William, Rombo, Lars, Hedner, Jan, Allen, Martin, Walker, Paul P, De Ryck, Iris, Tasciotti, Annaelisa, Casula, Daniela, Moris, Philippe, Testa, Marco, Arora, Ashwani K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Age Allergy and Immunology Antibodies Antigens CD4 antigen Chronic infection Chronic obstructive pulmonary disease Clinical trials Combined vaccines Confidence intervals COPD Exacerbation Haemophilus influenzae Immunization Immunogenicity Lung diseases Lymphocytes Lymphocytes T Microorganisms Non-typeable Haemophilus influenzae Obstructive lung disease Patients Pilin Protein D Proteins Respiratory tract Safety Smoking Statistical analysis Vaccination Vaccine Vaccine efficacy Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights•An investigational NTHi vaccine was tested for the first time in adults with COPD. •The vaccine had acceptable safety and reactogenicity. •Vaccine-elicited antibody concentrations were higher than baseline 1 year post-dose 2.
ISSN:	0264-410X 1873-2518 1873-2518
DOI:	10.1016/j.vaccine.2019.07.100